Otsuka commences unit's production in Rajasthan
indiatimes.com     May 16, 2008            

JAIPUR: Otsuka Chemical India (OCIL), a wholly-owned subsidiary of Japanese company Ostuka Chemical Co. Ltd, on Friday announced commencement of production of a bulk drug intermediate manufacturing unit built near Kotputli at a cost of Rs 150 crore. Rajasthan State Industrial Development &... [read full story]                    


View all news articles about*:
Chemical Facilities India Industry Japan Manufacturing Production
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Heroes: Season Two (Blu-Ray)

dvdauthority.com     1 hr ago          

Heroes was one of the runaway hits of the 2006-2007 television season and, as such, it had high expectations lauded upon it for its sophomore year. While the reviews were mixed, I personally enjoyed it though the onset...                    

comments

PAX 2008: Touring the Pink Godzilla booth

joystiq.com     1 hr ago          

Filed under: Culture, Galleries click to enter the store ... vicariously Despite what you may think from the picture, it wasn't the tower of pink plushies that attracted us to the Pink Godzilla store booth. More so, it was...                    

comments

                   

Ear membrane

turkishdailynews.com.tr     3 hrs ago          

only available in modern browsers."); } } MİTHAT MELEN Living in Istanbul you either get used to certain daily problem or you start not paying attention to them. I am talking about the high-pitched noises the human ear...                    

comments

                   

Roquette Pharma to Showcase its Comprehensive Range of Enabling Technologies at CPhI 2008

newswiretoday.com     9 hrs ago   1 related          

NewswireToday - /newswire/ - Roquette Pharma will be showcasing a selection of its key product ranges at CPhI Worldwide, Messe Frankfurt, Germany, September 30 – October 2, stand 60D05. Roquette Pharma, a longstanding...                    

comments